{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:25:58Z","timestamp":1786706758644,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS120949"],"award-info":[{"award-number":["R01NS120949"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS073611"],"award-info":[{"award-number":["R01NS073611"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS096754"],"award-info":[{"award-number":["R01NS096754"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA006973"],"award-info":[{"award-number":["P30CA006973"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["F99CA284254"],"award-info":[{"award-number":["F99CA284254"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA246699"],"award-info":[{"award-number":["R37CA246699"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA228133"],"award-info":[{"award-number":["R01CA228133"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["5P50HD103538-05"],"award-info":[{"award-number":["5P50HD103538-05"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"name":"John Camp and Mindy Farber '74 Endowed Award"},{"name":"Johns Hopkins University Provost\u2019s Undergraduate Research Award"},{"name":"Life Design Summer Experience Practicum"},{"name":"Summer Academic Research Experience and the Johns Hopkins Initiative for Careers in Science and Medicine"},{"DOI":"10.13039\/100000070","name":"U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["P41EB028239"],"award-info":[{"award-number":["P41EB028239"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"U.S. Department of Health & Human Services | NIH | NIH Office of the Director","doi-asserted-by":"publisher","award":["S10 OD016374"],"award-info":[{"award-number":["S10 OD016374"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Asbstract<\/jats:title>\n          <jats:p>Despite aggressive therapy, glioblastoma (GBM) recurs in almost all patients and treatment options are very limited. Despite our growing understanding of how cellular transitions associate with relapse in GBM, critical gaps remain in our ability to block these molecular changes and treat recurrent disease. In this study we combine computational biology, forward-thinking understanding of miRNA biology and cutting-edge nucleic acid delivery vehicles to advance targeted therapeutics for GBM. Computational analysis of RNA sequencing from clinical GBM specimens identified TGF\u03b2 type II receptor (TGFBR2) as a key player in the mesenchymal transition associated with worse outcome in GBM. Mechanistically, we show that elevated levels of TGFBR2 is conducive to reduced temozolomide (TMZ) sensitivity. This effect is, at least partially, induced by stem-cell driving events coordinated by the reprogramming transcription factors Oct4 and Sox2 that lead to open chromatin states. We show that blocking TGFBR2 via molecular and pharmacological approaches decreases stem cell capacity and sensitivity of clinical recurrent GBM (rGBM) isolates to TMZ in vitro. Network analysis uncovered miR-590-3p as a tumor suppressor that simultaneously inhibits multiple oncogenic nodes downstream of TGFBR2. We also developed novel biodegradable lipophilic poly(\u03b2-amino ester) nanoparticles (LiPBAEs) for in vivo microRNA (miRNAs) delivery. Following direct intra-tumoral infusion, these nanomiRs efficiently distribute through the tumors. Importantly, miR-590-3p nanomiRs inhibited the growth and extended survival of mice bearing orthotopic human rGBM xenografts, with an apparent 30% cure rate. These results show that miRNA-based targeted therapeutics provide new opportunities to treat rGBM and bypass the resistance to standard of care therapy.<\/jats:p>","DOI":"10.1038\/s41392-025-02223-w","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T23:03:36Z","timestamp":1745967816000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Multipronged SMAD pathway targeting by lipophilic poly(\u03b2-amino ester) miR-590-3p nanomiRs inhibits mesenchymal glioblastoma growth and prolongs survival"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3845-7869","authenticated-orcid":false,"given":"Jack","family":"Korleski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Sall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Luly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya K.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3055-945X","authenticated-orcid":false,"given":"Amanda L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1962-3844","authenticated-orcid":false,"given":"Harmon","family":"Khela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bachchu","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TC","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Micheal","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Smith-Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephany Y.","family":"Tzeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Laterra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4176-3808","authenticated-orcid":false,"given":"Jordan J.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6618-1092","authenticated-orcid":false,"given":"Hernando","family":"Lopez-Bertoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"2223_CR1","doi-asserted-by":"crossref","unstructured":"Zhang, M. et al. TGF-beta signaling and resistance to cancer therapy. Front Cell Dev Biol. 9, 786728.","DOI":"10.3389\/fcell.2021.786728"},{"key":"2223_CR2","doi-asserted-by":"publisher","first-page":"109638","DOI":"10.1016\/j.cellsig.2020.109638","volume":"72","author":"JL Birch","year":"2020","unstructured":"Birch, J. L., et al. Multifaceted transforming growth factor-beta (TGFbeta) signalling in glioblastoma. Cell Signal 72, 109638 (2020).","journal-title":"Cell Signal"},{"key":"2223_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-020-00436-9","volume":"6","author":"S Liu","year":"2021","unstructured":"Liu, S., Ren, J. & Ten Dijke, P. Targeting TGFbeta signal transduction for cancer therapy. Signal Transduct. Target Ther. 6, 8 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"2223_CR4","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.7150\/ijbs.66673","volume":"18","author":"B Li","year":"2022","unstructured":"Li, B., Chen, J., Wu, Y., Luo, H. & Ke, Y. Decrease of circARID1A retards glioblastoma invasion by modulating miR-370-3p\/ TGFBR2 pathway. Int. J. Biol. Sci. 18, 5123\u20135135 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"2223_CR5","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1074\/mcp.M115.049999","volume":"15","author":"Y Narushima","year":"2016","unstructured":"Narushima, Y. et al. Integrative network analysis combined with quantitative phosphoproteomics reveals transforming growth factor-beta receptor type-2 (TGFBR2) as a novel regulator of glioblastoma stem cell properties. Mol. Cell Proteom. 15, 1017\u20131031 (2016).","journal-title":"Mol. Cell Proteom."},{"key":"2223_CR6","first-page":"792","volume":"8","author":"K Song","year":"2018","unstructured":"Song, K. et al. ERBB3, IGF1R, and TGFBR2 expression correlate with PDGFR expression in glioblastoma and participate in PDGFR inhibitor resistance of glioblastoma cells. Am. J. Cancer Res. 8, 792\u2013809 (2018).","journal-title":"Am. J. Cancer Res."},{"key":"2223_CR7","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s10571-016-0338-3","volume":"36","author":"F Wei","year":"2016","unstructured":"Wei, F. et al. miR-373 Inhibits Glioma Cell U251 Migration and Invasion by Down-Regulating CD44 and TGFBR2. Cell Mol. Neurobiol. 36, 1389\u20131397 (2016).","journal-title":"Cell Mol. Neurobiol."},{"key":"2223_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05265-y","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou, X. et al. Recruitment of LEF1 by Pontin chromatin modifier amplifies TGFBR2 transcription and activates TGFbeta\/SMAD signalling during gliomagenesis. Cell Death Dis. 13, 818 (2022).","journal-title":"Cell Death Dis."},{"key":"2223_CR9","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","volume":"23","author":"QT Ostrom","year":"2021","unstructured":"Ostrom, Q. T., Cioffi, G., Waite, K., Kruchko, C. & Barnholtz-Sloan, J. S. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro Oncol. 23, iii1\u2013iii105 (2021).","journal-title":"Neuro Oncol."},{"key":"2223_CR10","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N. Engl. J. Med."},{"key":"2223_CR11","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel, C. et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell 178, 835\u2013849.e821 (2019).","journal-title":"Cell"},{"key":"2223_CR12","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396\u20131401 (2014).","journal-title":"Science"},{"key":"2223_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.stem.2016.11.003","volume":"20","author":"BB Liau","year":"2017","unstructured":"Liau, B. B. et al. Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance. Cell Stem Cell 20, 233\u2013246.e237 (2017).","journal-title":"Cell Stem Cell"},{"key":"2223_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nature11287","volume":"488","author":"J Chen","year":"2012","unstructured":"Chen, J. et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522\u2013526 (2012).","journal-title":"Nature"},{"key":"2223_CR15","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.1038\/onc.2014.334","volume":"34","author":"H Lopez-Bertoni","year":"2015","unstructured":"Lopez-Bertoni, H. et al. DNMT-dependent suppression of microRNA regulates the induction of GBM tumor-propagating phenotype by Oct4 and Sox2. Oncogene 34, 3994\u20134004 (2015).","journal-title":"Oncogene"},{"key":"2223_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RG Verhaak","year":"2010","unstructured":"Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98\u2013110 (2010).","journal-title":"Cancer Cell"},{"key":"2223_CR17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/brain\/awz044","volume":"142","author":"J Behnan","year":"2019","unstructured":"Behnan, J., Finocchiaro, G. & Hanna, G. The landscape of the mesenchymal signature in brain tumours. Brain 142, 847\u2013866 (2019).","journal-title":"Brain"},{"key":"2223_CR18","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.3390\/ijms19071901","volume":"19","author":"HI Suzuki","year":"2018","unstructured":"Suzuki, H. I. MicroRNA Control of TGF-beta Signaling. Int J. Mol. Sci. 19, 1901 (2018).","journal-title":"Int J. Mol. Sci."},{"key":"2223_CR19","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1091\/mbc.e11-02-0103","volume":"22","author":"PA Gregory","year":"2011","unstructured":"Gregory, P. A. et al. An autocrine TGF-beta\/ZEB\/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol. Biol. Cell 22, 1686\u20131698 (2011).","journal-title":"Mol. Biol. Cell"},{"key":"2223_CR20","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1021\/acs.nanolett.8b00390","volume":"18","author":"H Lopez-Bertoni","year":"2018","unstructured":"Lopez-Bertoni, H. et al. Bioreducible Polymeric Nanoparticles Containing Multiplexed Cancer Stem Cell Regulating miRNAs Inhibit Glioblastoma Growth and Prolong Survival. Nano Lett. 18, 4086\u20134094 (2018).","journal-title":"Nano Lett."},{"key":"2223_CR21","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/ng.127","volume":"40","author":"I Ben-Porath","year":"2008","unstructured":"Ben-Porath, I. et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40, 499\u2013507 (2008).","journal-title":"Nat. Genet."},{"key":"2223_CR22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.biocel.2017.12.002","volume":"94","author":"H Wang","year":"2018","unstructured":"Wang, H. et al. Overexpression of ELF3 facilitates cell growth and metastasis through PI3K\/Akt and ERK signaling pathways in non-small cell lung cancer. Int J. Biochem. Cell Biol. 94, 98\u2013106 (2018).","journal-title":"Int J. Biochem. Cell Biol."},{"key":"2223_CR23","doi-asserted-by":"crossref","unstructured":"Rosager, A. M. et al. Expression and prognostic value of JAM-A in gliomas. J. Neurooncol. 135, 107\u2013117.","DOI":"10.1007\/s11060-017-2555-0"},{"key":"2223_CR24","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1038\/onc.2015.199","volume":"35","author":"BY Ahn","year":"2016","unstructured":"Ahn, B. Y. et al. Glioma invasion mediated by the p75 neurotrophin receptor (p75(NTR)\/CD271) requires regulated interaction with PDLIM1. Oncogene 35, 1411\u20131422 (2016).","journal-title":"Oncogene"},{"key":"2223_CR25","doi-asserted-by":"publisher","first-page":"e1000319","DOI":"10.1371\/journal.pbio.1000319","volume":"8","author":"AB Hjelmeland","year":"2010","unstructured":"Hjelmeland, A. B. et al. Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol. 8, e1000319 (2010).","journal-title":"PLoS Biol."},{"key":"2223_CR26","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.1093\/hmg\/ddu148","volume":"23","author":"E Flex","year":"2014","unstructured":"Flex, E. et al. Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis. Hum. Mol. Genet. 23, 4315\u20134327 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"2223_CR27","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1158\/0008-5472.CAN-09-2886","volume":"70","author":"SS Kang","year":"2010","unstructured":"Kang, S. S. et al. Caffeine-mediated inhibition of calcium release channel inositol 1,4,5-trisphosphate receptor subtype 3 blocks glioblastoma invasion and extends survival. Cancer Res 70, 1173\u20131183 (2010).","journal-title":"Cancer Res"},{"key":"2223_CR28","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/j.cell.2022.04.038","volume":"185","author":"FS Varn","year":"2022","unstructured":"Varn, F. S. et al. Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell 185, 2184\u20132199.e2116 (2022).","journal-title":"Cell"},{"key":"2223_CR29","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s43018-022-00475-x","volume":"3","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets. Nat. Cancer 3, 1534\u20131552 (2022).","journal-title":"Nat. Cancer"},{"key":"2223_CR30","doi-asserted-by":"publisher","first-page":"4903","DOI":"10.1038\/onc.2016.22","volume":"35","author":"H Lopez-Bertoni","year":"2026","unstructured":"Lopez-Bertoni, H. et al. Epigenetic modulation of a miR-296-5p:HMGA1 axis regulates Sox2 expression and glioblastoma stem cells. Oncogene 35, 4903\u20134913 (2026).","journal-title":"Oncogene"},{"key":"2223_CR31","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.stem.2012.04.025","volume":"11","author":"E Willems","year":"2012","unstructured":"Willems, E. et al. Small molecule-mediated TGF-beta type II receptor degradation promotes cardiomyogenesis in embryonic stem cells. Cell Stem Cell 11, 242\u2013252 (2012).","journal-title":"Cell Stem Cell"},{"key":"2223_CR32","doi-asserted-by":"publisher","first-page":"6449","DOI":"10.1021\/acs.nanolett.8b02917","volume":"18","author":"JC Kaczmarek","year":"2018","unstructured":"Kaczmarek, J. C. et al. Optimization of a degradable polymer-lipid nanoparticle for potent systemic delivery of mRNA to the lung endothelium and immune cells. Nano Lett. 18, 6449\u20136454 (2018).","journal-title":"Nano Lett."},{"key":"2223_CR33","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1021\/acsbiomaterials.0c00116","volume":"6","author":"J Kim","year":"2020","unstructured":"Kim, J. et al. Poly(ethylene glycol)-Poly(beta-amino ester)-based nanoparticles for suicide gene therapy enhance brain penetration and extend survival in a preclinical human glioblastoma orthotopic xenograft model. ACS Biomater. Sci. Eng. 6, 2943\u20132955 (2020).","journal-title":"ACS Biomater. Sci. Eng."},{"key":"2223_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2026","unstructured":"Suk, J. S., Xu, Q., Kim, N., Hanes, J. & Ensign, L. M. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99, 28\u201351 (2026).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2223_CR35","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/ng.3590","volume":"48","author":"J Wang","year":"2016","unstructured":"Wang, J. et al. Clonal evolution of glioblastoma under therapy. Nat. Genet. 48, 768\u2013776 (2016).","journal-title":"Nat. Genet."},{"key":"2223_CR36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ccr.2006.02.019","volume":"9","author":"HS Phillips","year":"2006","unstructured":"Phillips, H. S. et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157\u2013173 (2006).","journal-title":"Cancer Cell"},{"key":"2223_CR37","doi-asserted-by":"publisher","first-page":"745","DOI":"10.15252\/emmm.201606184","volume":"8","author":"E Fessler","year":"2016","unstructured":"Fessler, E. et al. TGFbeta signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype. EMBO Mol. Med. 8, 745\u2013760 (2016).","journal-title":"EMBO Mol. Med."},{"key":"2223_CR38","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nm.2344","volume":"17","author":"EA Collisson","year":"2011","unstructured":"Collisson, E. A. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500\u2013503 (2011).","journal-title":"Nat. Med."},{"key":"2223_CR39","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ccr.2012.12.020","volume":"23","author":"D Yang","year":"2013","unstructured":"Yang, D. et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 23, 186\u2013199 (2013).","journal-title":"Cancer Cell"},{"key":"2223_CR40","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.cell.2013.09.041","volume":"155","author":"HS Kim","year":"2013","unstructured":"Kim, H. S. et al. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell 155, 552\u2013566 (2013).","journal-title":"Cell"},{"key":"2223_CR41","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fnmol.2017.00068","volume":"10","author":"W Zhou","year":"2017","unstructured":"Zhou, W. et al. Combination of Endothelial-Monocyte-Activating Polypeptide-II with Temozolomide Suppress Malignant Biological Behaviors of Human Glioblastoma Stem Cells via miR-590-3p\/MACC1 Inhibiting PI3K\/AKT\/mTOR Signal Pathway. Front Mol. Neurosci. 10, 68 (2017).","journal-title":"Front Mol. Neurosci."},{"key":"2223_CR42","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.bbrc.2015.11.025","volume":"468","author":"H Pang","year":"2016","unstructured":"Pang, H., Zheng, Y., Zhao, Y., Xiu, X. & Wang, J. miR-590-3p suppresses cancer cell migration, invasion and epithelial-mesenchymal transition in glioblastoma multiforme by targeting ZEB1 and ZEB2. Biochem. Biophys. Res. Commun. 468, 739\u2013745 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2223_CR43","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/neuonc\/noq142","volume":"13","author":"U Bogdahn","year":"2011","unstructured":"Bogdahn, U. et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 13, 132\u2013142 (2011).","journal-title":"Neuro Oncol."},{"key":"2223_CR44","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1093\/neuonc\/now009","volume":"18","author":"AA Brandes","year":"2016","unstructured":"Brandes, A. A. et al. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro Oncol. 18, 1146\u20131156 (2016).","journal-title":"Neuro Oncol."},{"key":"2223_CR45","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/s12276-023-01050-9","volume":"55","author":"T Kim","year":"2023","unstructured":"Kim, T. & Croce, C. M. MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies. Exp. Mol. Med 55, 1314\u20131321 (2023).","journal-title":"Exp. Mol. Med"},{"key":"2223_CR46","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11060-023-04552-8","volume":"166","author":"D Kreatsoulas","year":"2024","unstructured":"Kreatsoulas, D., Damante, M., Cua, S. & Lonser, R. R. Adjuvant convection-enhanced delivery for the treatment of brain tumors. J. Neurooncol 166, 243\u2013255 (2024).","journal-title":"J. Neurooncol"},{"key":"2223_CR47","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1470-2045(22)00599-X","volume":"23","author":"EF Spinazzi","year":"2022","unstructured":"Spinazzi, E. F. et al. Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial. Lancet Oncol. 23, 1409\u20131418 (2022).","journal-title":"Lancet Oncol."},{"key":"2223_CR48","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa1716435","volume":"379","author":"A Desjardins","year":"2018","unstructured":"Desjardins, A. et al. Recurrent glioblastoma treated with recombinant poliovirus. N. Engl. J. Med. 379, 150\u2013161 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2223_CR49","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41578-022-00529-7","volume":"8","author":"SA Dilliard","year":"2023","unstructured":"Dilliard, S. A. & Siegwart, D. J. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat. Rev. Mater. 8, 282\u2013300 (2023).","journal-title":"Nat. Rev. Mater."},{"key":"2223_CR50","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jconrel.2023.03.052","volume":"362","author":"S Kimura","year":"2023","unstructured":"Kimura, S. & Harashima, H. On the mechanism of tissue-selective gene delivery by lipid nanoparticles. J. Control Release 362, 797\u2013811 (2023).","journal-title":"J. Control Release"},{"key":"2223_CR51","doi-asserted-by":"publisher","first-page":"7011","DOI":"10.1158\/0008-5472.CAN-04-1364","volume":"64","author":"R Galli","year":"2004","unstructured":"Galli, R. et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64, 7011\u20137021 (2004).","journal-title":"Cancer Res."},{"key":"2223_CR52","doi-asserted-by":"publisher","first-page":"8644","DOI":"10.1073\/pnas.1221478110","volume":"110","author":"P Mao","year":"2013","unstructured":"Mao, P. et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc. Natl. Acad. Sci. USA 110, 8644\u20138649 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2223_CR53","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1158\/1078-0432.CCR-19-0909","volume":"26","author":"RA Vaubel","year":"2020","unstructured":"Vaubel, R. A. et al. Genomic and phenotypic characterization of a broad panel of patient-derived xenografts reflects the diversity of glioblastoma. Clin. Cancer Res. 26, 1094\u20131104 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2223_CR54","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41392-021-00857-0","volume":"7","author":"H Lopez-Bertoni","year":"2022","unstructured":"Lopez-Bertoni, H. et al. Sox2 induces glioblastoma cell stemness and tumor propagation by repressing TET2 and deregulating 5hmC and 5mC DNA modifications. Signal Transduct. Target Ther. 7, 37 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"2223_CR55","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abk2855","volume":"8","author":"Y Rui","year":"2022","unstructured":"Rui, Y. et al. High-throughput and high-content bioassay enables tuning of polyester nanoparticles for cellular uptake, endosomal escape, and systemic in vivo delivery of mRNA. Sci. Adv. 8, eabk2855 (2022).","journal-title":"Sci. Adv."},{"key":"2223_CR56","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/nmeth.2688","volume":"10","author":"JD Buenrostro","year":"2013","unstructured":"Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods 10, 1213\u20131218 (2013).","journal-title":"Nat. Methods"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02223-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02223-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02223-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T23:03:40Z","timestamp":1745967820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02223-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2223"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02223-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"17 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.G. and S.T. are managers and co-founders of OncoSwitch. J.G. is a board member, CSO, and co-founder of Cove Therapeutics and a manager, CTO, and co-founder of Dome Therapeutics. Patents related to the technology discussed in the manuscript and any potential conflicts of interest are managed by the Johns Hopkins University Committee on Outside Interests. There are no competing interests from the other authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"145"}}